Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 103

1.

FOLFOX plus anti-epidermal growth factor receptor (EGFR) monoclonal antibody (mAb) is an effective first-line treatment for patients with RAS-wild left-sided metastatic colorectal cancer: A meta-analysis.

Chen D, Li L, Zhang X, Gao G, Shen L, Hu J, Yang M, Liu B, Qian X.

Medicine (Baltimore). 2018 Mar;97(10):e0097. doi: 10.1097/MD.0000000000010097. Review.

2.

[A Case of Ascending Colon Cancer with Synchronous Liver Metastases and Peritoneal Dissemination].

Mito M, Kameyama H, Shimada Y, Yamada S, Hotta S, Hirose Y, Yagi R, Tajima Y, Nakano M, Okamura T, Nakano M, Ichikawa H, Nagahashi M, Sakata J, Wakai T.

Gan To Kagaku Ryoho. 2017 Nov;44(12):1126-1128. Japanese.

PMID:
29394555
3.

Correlations between microsatellite instability, ERCC1/XRCC1 polymorphism and clinical characteristics, and FOLFOX adjuvant chemotherapy effect of colorectal cancer patients.

Zhang L, Zhao J, Yu B, Song X, Sun G, Han L, Wang L, Dong S.

Cancer Genet. 2017 Dec;218-219:51-57. doi: 10.1016/j.cancergen.2017.09.004. Epub 2017 Sep 22.

4.
5.

Association of DNA Mismatch Repair and Mutations in BRAF and KRAS With Survival After Recurrence in Stage III Colon Cancers : A Secondary Analysis of 2 Randomized Clinical Trials.

Sinicrope FA, Shi Q, Allegra CJ, Smyrk TC, Thibodeau SN, Goldberg RM, Meyers JP, Pogue-Geile KL, Yothers G, Sargent DJ, Alberts SR.

JAMA Oncol. 2017 Apr 1;3(4):472-480. doi: 10.1001/jamaoncol.2016.5469.

6.

FGFR4 Arg388 Is Correlated with Poor Survival in Resected Colon Cancer Promoting Epithelial to Mesenchymal Transition.

Cho SH, Hong CS, Kim HN, Shin MH, Kim KR, Shim HJ, Hwang JE, Bae WK, Chung IJ.

Cancer Res Treat. 2017 Jul;49(3):766-777. doi: 10.4143/crt.2016.457. Epub 2016 Nov 9.

7.

Microsatellite Instability was not Associated with Survival in Stage III Colon Cancer Treated with Adjuvant Chemotherapy of Oxaliplatin and Infusional 5-Fluorouracil and Leucovorin (FOLFOX).

Kim JE, Hong YS, Kim HJ, Kim KP, Kim SY, Lim SB, Park IJ, Kim CW, Yoon YS, Yu CS, Kim JC, Kim JH, Kim TW.

Ann Surg Oncol. 2017 May;24(5):1289-1294. doi: 10.1245/s10434-016-5682-5. Epub 2016 Nov 16.

PMID:
27853901
8.

Subgroup analysis in RAISE: a randomized, double-blind phase III study of irinotecan, folinic acid, and 5-fluorouracil (FOLFIRI) plus ramucirumab or placebo in patients with metastatic colorectal carcinoma progression.

Obermannová R, Van Cutsem E, Yoshino T, Bodoky G, Prausová J, Garcia-Carbonero R, Ciuleanu T, Garcia Alfonso P, Portnoy D, Cohn A, Yamazaki K, Clingan P, Lonardi S, Kim TW, Yang L, Nasroulah F, Tabernero J.

Ann Oncol. 2016 Nov;27(11):2082-2090. Epub 2016 Aug 29.

9.

Randomized study of FOLFIRI plus either panitumumab or bevacizumab for wild-type KRAS colorectal cancer-WJOG 6210G.

Shitara K, Yonesaka K, Denda T, Yamazaki K, Moriwaki T, Tsuda M, Takano T, Okuda H, Nishina T, Sakai K, Nishio K, Tokunaga S, Yamanaka T, Boku N, Hyodo I, Muro K.

Cancer Sci. 2016 Dec;107(12):1843-1850. doi: 10.1111/cas.13098.

10.

[KRAS mutation does not influence oxaliplatin or irinotecan efficacy, in association with bevacizumab, in first line treatment of metastatic colorectal cancer].

Cabart M, Frénel JS, Campion L, Ramée JF, Dupuis O, Senellart H, Hiret S, Douillard JY, Bennouna J.

Bull Cancer. 2016 Jun;103(6):541-51. doi: 10.1016/j.bulcan.2016.03.007. Epub 2016 May 5. French.

PMID:
27155924
11.

Associations and prognostic implications of Eastern Cooperative Oncology Group performance status and tumoral LINE-1 methylation status in stage III colon cancer patients.

Chen D, Wen X, Song YS, Rhee YY, Lee TH, Cho NY, Han SW, Kim TY, Kang GH.

Clin Epigenetics. 2016 Apr 5;8:36. doi: 10.1186/s13148-016-0203-8. eCollection 2016.

12.

Reconsidering the benefit of intermittent versus continuous treatment in the maintenance treatment setting of metastatic colorectal cancer.

Sunakawa Y, Bekaii-Saab T, Stintzing S.

Cancer Treat Rev. 2016 Apr;45:97-104. doi: 10.1016/j.ctrv.2016.03.007. Epub 2016 Mar 14. Review.

PMID:
27002945
13.

Pancreatic cancer.

Kamisawa T, Wood LD, Itoi T, Takaori K.

Lancet. 2016 Jul 2;388(10039):73-85. doi: 10.1016/S0140-6736(16)00141-0. Epub 2016 Jan 30. Review.

PMID:
26830752
14.

Successful Treatment with Modified FOLFOX6 and Panitumumab in a Cecal Cancer Patient Undergoing Hemodialysis.

Kobayashi M, Endo S, Hamano Y, Imanishi M, Akutsu D, Sugaya A, Ochi D, Moriwaki T, Hyodo I.

Intern Med. 2016;55(2):127-30. doi: 10.2169/internalmedicine.55.5113. Epub 2016 Jan 15.

15.

Prognostic Effect of BRAF and KRAS Mutations in Patients With Stage III Colon Cancer Treated With Leucovorin, Fluorouracil, and Oxaliplatin With or Without Cetuximab: A Post Hoc Analysis of the PETACC-8 Trial.

Taieb J, Zaanan A, Le Malicot K, Julié C, Blons H, Mineur L, Bennouna J, Tabernero J, Mini E, Folprecht G, Van Laethem JL, Lepage C, Emile JF, Laurent-Puig P.

JAMA Oncol. 2016 Jan 14:1-11. doi: 10.1001/jamaoncol.2015.5225. [Epub ahead of print]

PMID:
26768652
16.

Phase II study of necitumumab plus modified FOLFOX6 as first-line treatment in patients with locally advanced or metastatic colorectal cancer.

Elez E, Hendlisz A, Delaunoit T, Sastre J, Cervantes A, Varea R, Chao G, Wallin J, Tabernero J.

Br J Cancer. 2016 Feb 16;114(4):372-80. doi: 10.1038/bjc.2015.480. Epub 2016 Jan 14.

17.

Singapore Cancer Network (SCAN) Guidelines for Systemic Therapy of Colorectal Cancer.

Singapore Cancer Network (SCAN) Colorectal Cancer Systemic Therapy Workgroup.

Ann Acad Med Singapore. 2015 Oct;44(10):379-87.

18.

BRAF Mutation Testing and Metastatic Colorectal Cancer in the Community Setting: Is There an Urgent Need for More Education?

Price TJ, Beeke C, Townsend AR, Lo L, Amitesh R, Padbury R, Roder D, Maddern G, Moore J, Karapetis C.

Mol Diagn Ther. 2016 Feb;20(1):75-82. doi: 10.1007/s40291-015-0179-7.

PMID:
26714964
19.

Cetuximab Plus Various Chemotherapy Regimens for Patients with KRAS Wild-Type Metastatic Colorectal Cancer.

Azadeh P, Mortazavi N, Tahmasebi A, Hosseini Kamal F, Novin K.

Chemotherapy. 2016;61(1):51-6. doi: 10.1159/000440693. Epub 2015 Nov 4.

PMID:
26528862
20.

Adjuvant Fluorouracil, Leucovorin, and Oxaliplatin in Stage II to III Colon Cancer: Updated 10-Year Survival and Outcomes According to BRAF Mutation and Mismatch Repair Status of the MOSAIC Study.

André T, de Gramont A, Vernerey D, Chibaudel B, Bonnetain F, Tijeras-Raballand A, Scriva A, Hickish T, Tabernero J, Van Laethem JL, Banzi M, Maartense E, Shmueli E, Carlsson GU, Scheithauer W, Papamichael D, Möehler M, Landolfi S, Demetter P, Colote S, Tournigand C, Louvet C, Duval A, Fléjou JF, de Gramont A.

J Clin Oncol. 2015 Dec 10;33(35):4176-87. doi: 10.1200/JCO.2015.63.4238. Epub 2015 Nov 2.

PMID:
26527776

Supplemental Content

Loading ...
Support Center